Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02385669 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
A Phase 1 study, sponsored by Craig L Slingluff, Jr.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02385669: Clinical Trial Phase 1 study, sponsored by Craig L Slingluff, Jr.
NCT02385669 is a Phase 1 study that was terminated before completion, run by Craig L Slingluff, Jr. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02385669, a Phase 1 study, was terminated before completion, sponsored by Craig L Slingluff, Jr.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study evaluates whether it is safe to administer a peptide vaccine with ipilimumab. This study will also evaluate the effects of the combination of the peptide vaccine and ipilimumab on the immune system. The investigators will monitor these effects by performing tests in the laboratory on participants' blood, a lymph node, and tumor samples.
Primary Outcome
Adverse event profile for the combination of ipilimumab and 6MHP
Interventions
- DRUG Ipilimumab
- BIOLOGICAL 6MHP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-09-18 |
| Phase | Phase 1 |
Why NCT02385669 stopped before completion
NCT02385669 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT02385669 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02385669 about?
NCT02385669 is a clinical study titled "A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma". This study evaluates whether it is safe to administer a peptide vaccine with ipilimumab. This study will also evaluate the effects of the combination of the peptide vaccine and ipilimumab on the immune system. The investigators will monitor these effects by performing tests in the laboratory on part...
What is the current status of trial NCT02385669?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2015-04. Estimated completion is 2019-09-18.
What interventions are being tested in trial NCT02385669?
The interventions under investigation include: Ipilimumab (DRUG), 6MHP (BIOLOGICAL).
Who is sponsoring clinical trial NCT02385669?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02385669's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia